STTK vs. VRCA, KRRO, NGNE, ESPR, MREO, TERN, HRTX, ANRO, ORGO, and AMRN
Should you be buying Shattuck Labs stock or one of its competitors? The main competitors of Shattuck Labs include Verrica Pharmaceuticals (VRCA), Korro Bio (KRRO), Neurogene (NGNE), Esperion Therapeutics (ESPR), Mereo BioPharma Group (MREO), Terns Pharmaceuticals (TERN), Heron Therapeutics (HRTX), Alto Neuroscience (ANRO), Organogenesis (ORGO), and Amarin (AMRN). These companies are all part of the "pharmaceutical preparations" industry.
Verrica Pharmaceuticals (NASDAQ:VRCA) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, community ranking, risk and media sentiment.
42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 42.6% of Verrica Pharmaceuticals shares are owned by company insiders. Comparatively, 10.5% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than Shattuck Labs. MarketBeat recorded 12 mentions for Verrica Pharmaceuticals and 11 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 0.54 beat Verrica Pharmaceuticals' score of 0.36 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.
Verrica Pharmaceuticals has higher revenue and earnings than Shattuck Labs. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.
Verrica Pharmaceuticals currently has a consensus price target of $13.50, indicating a potential upside of 52.20%. Shattuck Labs has a consensus price target of $20.00, indicating a potential upside of 156.08%. Given Verrica Pharmaceuticals' higher possible upside, analysts plainly believe Shattuck Labs is more favorable than Verrica Pharmaceuticals.
Verrica Pharmaceuticals has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, Shattuck Labs has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500.
Verrica Pharmaceuticals has a net margin of -905.83% compared to Verrica Pharmaceuticals' net margin of -3,133.63%. Verrica Pharmaceuticals' return on equity of -64.85% beat Shattuck Labs' return on equity.
Verrica Pharmaceuticals received 134 more outperform votes than Shattuck Labs when rated by MarketBeat users. However, 76.32% of users gave Shattuck Labs an outperform vote while only 64.94% of users gave Verrica Pharmaceuticals an outperform vote.
Summary
Verrica Pharmaceuticals beats Shattuck Labs on 9 of the 17 factors compared between the two stocks.
Get Shattuck Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for STTK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Shattuck Labs Competitors List
Related Companies and Tools
